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Abstract: We compared the INSTI
TM HIV-1 Antibody Point-of-Care (POC) Test to laboratory-based tests for detection of 
early sero-conversion (i.e. acute) HIV infections. Fifty-three (53) individuals with early HIV infection, (i.e. 3
rd generation 
anti-HIV EIA non-reactive or reactive, HIV-1 Western Blot non-reactive or indeterminate and HIV-1 p24 antigen 
reactive) were tested by INSTI
TM. The INSTI
TM test was reactive for 34/49 (sensitivity 69.4%; 95% confidence interval 
54.6-81.8%) early-infected individuals whose laboratory-based 3
rd generation HIV EIA test was reactive. Four (4) were 
non-reactive by both the laboratory-based EIA and INSTI
TM tests, but were p24 antigen reactive. The INSTI
TM POC test 
performs well compared with other POC tests for the detection of early sero-conversion HIV infection, but it may miss 
20% to 30% of those detected by laboratory-based 3
rd generation anti-HIV tests. Both POC and laboratory-based anti-HIV 
tests will fail to detect a proportion of infected individuals in the first weeks after infection. 
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FINDINGS 
  Acute HIV infections contribute significantly to the risk 
of secondary infections since acutely-infected individuals 
(i.e. during the early sero-conversion period) have very high 
viral loads and many are unaware of their infection [1, 2]. 
Current standard-of-care 3
rd generation anti-HIV tests are 
inadequate to identify a proportion of HIV-infected 
individuals during the early sero-conversion phase and 
additional tests to identify HIV p24 antigen or HIV RNA are 
required [3, 4]. Widespread application of HIV testing and 
early diagnosis are important to identify HIV-infected 
individuals to support effective prevention and care. In order 
to provide counseling regarding the accuracy of the various 
tests and for planning HIV testing programs, it is important 
to know the relative effectiveness of HIV point-of-care 
(POC)  vs laboratory-based tests for detecting early sero-
conversion HIV infections. In Canada, the INSTI
TM HIV-1 
Antibody Test (bioLytical Laboratories, Richmond BC) is 
the only licensed POC HIV test and its overall sensitivity 
and specificity are similar to laboratory-based 3
rd generation 
enzyme immunoassay (EIA) tests [5]. The manufacturer 
makes no specific sensitivity claims regarding the early sero-
conversion phase of HIV infection, but data from testing of 
25 sero-conversion panels are available [5]. For 15 panels, 
the INSTI
TM test became reactive on the same bleed, for 
seven panels one bleed later and for one panel two bleeds 
later than the referent 3
rd generation laboratory EIA. For two 
panels, the INSTI
TM test was non-reactive on the final bleed 
in the panel. The sensitivities of other POC tests for   
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detection of early sero-conversion HIV infection have been 
reported to be lower than for laboratory-based tests [3, 6-9]. 
  The objective of this study was to assess the sensitivity of 
the INSTI
TM test compared to laboratory-based HIV tests, 
using residual sera collected from individuals with early 
sero-conversion HIV infection. The study period was Feb 
2006 to Oct 2008. Presumptive early sero-conversion HIV 
infection was based on laboratory criteria, i.e. 3
rd generation 
anti-HIV EIA (Siemens ADVIA
TM Centaur HIV-1/O/2) non-
reactive or reactive, HIV-1 Western Blot (WB) (BioRad 
Genetic Systems HIV-1 Western Blot) non-reactive or 
indeterminate and HIV-1 p24 antigen (Biomérieux 
Vironostika HIV-1 Antigen) reactive with confirmation by 
neutralization or by HIV nucleic acid testing (NAT) (Roche 
AMPLICOR
TM HIV-1 DNA Test v. 1.5). WB interpretation 
criteria were: non-reactive (no bands are present); 
indeterminate (one or more bands are present but the blot 
does not meet reactive test criteria); reactive [at least two 
major bands (gp160 and/or gp120; gp41 or p24) must be 
present]. Cases were excluded if: there was insufficient 
residual serum for testing; the initial presumptive early sero-
conversion HIV result was not confirmed by follow-up WB, 
NAT or physician-reported viral load result; or individuals 
were known to have advanced HIV disease at diagnosis 
based on receipt of an AIDS case report within 12 months of 
a presumptive early sero-conversion HIV result. All subjects 
gave informed consent for HIV testing. The study was 
approved by the University of British Columbia Clinical 
Ethics Review Board. 
  Sixty-one (61) presumptive early sero-conversion HIV 
infections were identified, of which eight were excluded 
(four had insufficient residual serum for testing, two were 
cases which had no follow-up confirmatory WB testing, and 
two had an AIDS case report received within 12 months of INSTI
TM HIV-1 Test for Early Sero-Conversion HIV Infection  The Open AIDS Journal, 2010, Volume 4    177 
the presumptive early sero-conversion HIV result). Thus, 
specimens from 53 individuals were available for analysis. 
In addition, 10 serum samples from HIV-uninfected 
individuals (laboratory 3
rd generation EIA non-reactive) 
were tested, but there was no intent to evaluate the 
specificity of the INSTI
TM assay, which has already been 
established [5]. 
  Demographic characteristics of the early sero-conversion 
HIV cases were: 85% male; mean age 39 years; 95% HIV-1 
sub-type B; 71% Caucasian; 59% men who have sex with 
men (MSM), 25% injection drug user (IDU), and 20% 
heterosexual, non-IDU (individuals may report more than 
one exposure category). The demographics of the early sero-
conversion HIV cases were not significantly different from 
those of 926 other newly-identified HIV infections 
diagnosed during the study period, except that the early sero-
conversion cases were more likely to be MSM [unadjusted 
odds ratio 1.71; 95% confidence interval (CI) 1.01-2.89]. Of 
the 53 early sero-conversion HIV specimens, four were 
laboratory EIA non-reactive but p24 antigen reactive and 49 
were laboratory EIA reactive. The laboratory EIA protocol 
incorporates a 10% grey zone; specimens falling within the 
grey zone on initial testing are re-tested, and, if still in the 
grey zone are subjected to confirmatory testing. All residual 
initial specimens and any available follow-up specimens 
were tested by INSTI
TM. Each INSTI
TM test was interpreted 
by three technologists; in case of disagreement, the 
consensus interpretation was used. Interpretation criteria for 
the INSTI
TM test are: invalid (the control spot is not visible); 
non-reactive (the control spot is visible but there is no visible 
reaction on the test spot); indeterminate (the control spot is 
visible and a faint background ring appears on the test spot); 
reactive (the test spot and control spot are both visible). 
  The 10 laboratory EIA non-reactive specimens from 
uninfected individuals were non-reactive by INSTI
TM. As 
would be expected, the four laboratory EIA non-reactive, 
p24 antigen reactive early sero-conversion specimens were 
also non-reactive by INSTI
TM. Even when incorporating the 
10% grey zone for the laboratory EIA, all four were non-
reactive. Testing for early sero-conversion infection would 
have been specifically requested for these individuals (e.g. 
following a risk event or because of symptoms compatible 
with acute HIV infection); all four individuals became 
reactive by INSTI
TM and the laboratory EIA on follow-up 
testing (Table 1). Of the 49 laboratory EIA reactive early 
sero-conversion specimens, the INSTI
TM test was reactive 
for 34/49 (69.4%), indeterminate for 5/49 (10.2%) and non-
reactive for 10/49 (20.4%). Thus, the sensitivity of INSTI
TM 
compared to the laboratory EIA for detection of early sero-
conversion HIV infection in this population was 69.4% (95% 
CI 54.6-81.8%). There was no statistically significant 
association between an individual’s exposure category and a 
reactive INSTI
TM result. 
  The five INSTI
TM indeterminate initial specimens would 
normally be submitted for confirmatory laboratory testing, as 
recommended by the manufacturer, and this would have 
been expected to confirm early sero-conversion HIV 
infection. Thus, in practice, the initial INSTI
TM test results 
would likely have led to the correct screening diagnosis for 
39/49 (79.6%) of these early infections. Of the 15 INSTI
TM 
indeterminate and non-reactive initial specimens, the 
INSTI
TM test became reactive on 13/13 (100%) individuals 
who had follow-up specimens at a later date (Table 1). The 
other two individuals had follow-up serology which 
confirmed HIV infection, but there was insufficient residual 
serum available for INSTI
TM testing. 
 Louie, et al. [6] reported that of US-licensed rapid and 
POC HIV tests, the most sensitive assay detected 11/42 
(26.2%) early sero-conversion infections. These results may 
not be directly comparable to those in our study, as the 
specimens examined by Louie, et al. were selected from 
acute infections diagnosed by pooled NAT testing of pre-
screened 1
st generation EIA non-reactive specimens, and 
might reflect sampling earlier during infection. Our results 
are consistent with the findings of Giles, et al. [7], who 
reported that of 13 simple/rapid HIV test devices, none 
detected sero-conversion earlier than the most sensitive 
laboratory EIAs and four performed similarly. Laforgerie, et 
al. [8] recently reported that for eight CE (European 
Community)-approved rapid disposable tests, including the 
INSTI
TM test, earliest detection among three sero-conversion 
panels was variable. The INSTI
TM test detected two panels at 
the same time and for one panel, one bleed later than the 
earliest detection by any rapid test. It is possible that POC 
test sensitivity is related to the input sample volume used for 
testing. The INSTI
TM test utilizes 50L of sample, a larger 
volume than many other rapid/POC tests. 
  This study has several limitations. Interpretation of 
results of POC tests performed by trained technologists in a 
laboratory setting may not be directly generalizable to a 
clinical setting. It is recognized that necessary quality 
assurance practices must be in place for accurate POC testing 
and that non-laboratory or inexperienced health care 
providers may have difficulties in test result interpretation 
[10]. A potential source of study bias is that the technologists 
reading the tests were not blinded to the HIV sero-status of 
the samples; however, three technologists interpreted each 
result identically, except for one sample which was read as 
indeterminate by one technologist and non-reactive by the 
other two. It is also recognized that individuals with 
advanced HIV disease may have HIV serological result 
patterns similar to acute cases, i.e. 3
rd generation EIA 
reactive, p24 antigen reactive, WB indeterminate. None of 
the 53 early sero-conversion cases had an associated AIDS 
report within 12 months of diagnosis; however, due to 
incomplete and delayed AIDS reporting, it might be feasible 
that some individuals with advanced HIV infection were 
mis-classified as early sero-conversion. Given that only 
residual specimens of known sero-status were assessed, we 
could not identify individuals with early sero-conversion 
HIV infection who might have had a reactive INSTI
TM test at 
the same time as, or prior to, a non-reactive laboratory EIA, 
as has been reported for other POC tests [6]. This analysis 
involved residual serum, whereas in clinical practice, the 
INSTI
TM POC test uses whole blood which has been shown 
to provide equivalent results [5]. The study was not designed 
to assess the overall specificity of the INSTI
TM test nor the 178    The Open AIDS Journal, 2010, Volume 4  Cook et al. 
specificity amongst individuals who present with possible 
HIV sero-conversion symptoms. The study was carried out 
using a single batch of INSTI
TM tests and the possibility of 
lot-to-lot variability for the detection of early sero-
conversion infections cannot be excluded. 
  In summary, although most early sero-conversion HIV 
infections in our study were detected by INSTI
TM at the time 
of the initial specimen draw, 20-30% of early-infected 
individuals would have been missed. At least one 4
th 
generation POC test, which is able to detect both anti-HIV 
and p24 antigen, is available and others are in development. 
Until 4
th generation POC tests are widely adopted and are 
shown to reliably detect early sero-conversion HIV infection, 
combining POC testing with laboratory-based NAT or 4
th 
generation EIA testing could improve detection of early 
sero-conversion HIV infections in high incidence settings, 
and this has been recommended by others [3, 4]. 
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Table 1.  Results of Follow-Up Testing of INSTI
TM Non-Reactive or Indeterminate Early HIV Sero-Conversion Specimens 
 
Initial Specimens
a Follow-Up  Specimens
b 
Case # 
Siemens ADVIA Centaur  
EIA (Signal/Cutoff) 
Siemens ADVIA  
Centaur EIA Result
 
INSTI
TM  
Result 
Siemens ADVIA  
Centaur EIA Result 
INSTI
TM  
Result 
Days From Initial to INSTI
TM  
Reactive Followup Specimen
d 
3  0.8  NR  NR  R  R  49 
6  0.8  NR  NR  R  R  251 
18  <0.05  NR  NR  R  R  16 
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51  1.0  R  Indet  NT  R  20 
7  4.0  R  NR  R  NSQ   
9  10.4  R  NR  R  R  42 
11  8.1  R  NR  R  R  73 
21  >50  R  NR  R  R  26 
25  1.3  R  NR  R  NSQ   
31  41.0  R  NR  R  R  8 
37  13.8  R  NR  R  R  8 
49  2.5  R  NR  R  R  22 
57  1.2  R  NR  R  R
c  12 
60  3.3  R  NR  R  R  7 
NR=non-reactive; R=reactive; Indet=indeterminate; NSQ=insufficient quantity; NT=not tested. 
aAll specimens were HIV-1 p24 antigen confirmed reactive. 
bAll specimens were HIV-1 Western Blot positive. 
cA follow-up specimen collected 7 days after the initial specimen was INSTI
TM indeterminate. 
dMean and median times from initial to INSTI
TM reactive follow-up specimen are 41 and 20 days, respectively. INSTI
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